Concepts (123)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Opioid-Related Disorders | 5 | 2024 | 465 | 1.280 |
Why?
|
| Delay Discounting | 1 | 2020 | 3 | 0.730 |
Why?
|
| Intimate Partner Violence | 2 | 2017 | 26 | 0.700 |
Why?
|
| Drug Overdose | 2 | 2020 | 119 | 0.660 |
Why?
|
| Anxiety | 3 | 2017 | 395 | 0.610 |
Why?
|
| Motivation | 1 | 2020 | 266 | 0.600 |
Why?
|
| Crime Victims | 2 | 2017 | 32 | 0.590 |
Why?
|
| Sex Offenses | 2 | 2017 | 46 | 0.590 |
Why?
|
| Self-Control | 1 | 2017 | 6 | 0.590 |
Why?
|
| Stalking | 1 | 2017 | 2 | 0.580 |
Why?
|
| Depressive Disorder, Major | 7 | 2012 | 258 | 0.530 |
Why?
|
| Adaptation, Psychological | 2 | 2017 | 263 | 0.520 |
Why?
|
| Anxiety Disorders | 1 | 2017 | 188 | 0.500 |
Why?
|
| Emotions | 1 | 2017 | 217 | 0.490 |
Why?
|
| Stress Disorders, Post-Traumatic | 3 | 2020 | 365 | 0.360 |
Why?
|
| Opiate Substitution Treatment | 3 | 2022 | 192 | 0.360 |
Why?
|
| Antidepressive Agents | 5 | 2011 | 227 | 0.350 |
Why?
|
| Veterans | 4 | 2021 | 722 | 0.340 |
Why?
|
| Analgesics, Opioid | 2 | 2024 | 493 | 0.300 |
Why?
|
| Patient Discharge | 2 | 2022 | 479 | 0.300 |
Why?
|
| Students | 2 | 2017 | 207 | 0.240 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2011 | 666 | 0.240 |
Why?
|
| Humans | 22 | 2024 | 59320 | 0.200 |
Why?
|
| Chronic Pain | 1 | 2024 | 142 | 0.200 |
Why?
|
| Acupuncture Therapy | 2 | 2012 | 13 | 0.190 |
Why?
|
| Aftercare | 1 | 2022 | 67 | 0.190 |
Why?
|
| Treatment Outcome | 8 | 2022 | 5142 | 0.180 |
Why?
|
| Buprenorphine | 2 | 2021 | 186 | 0.180 |
Why?
|
| Residential Treatment | 1 | 2020 | 34 | 0.180 |
Why?
|
| Self Efficacy | 1 | 2020 | 201 | 0.170 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2020 | 117 | 0.160 |
Why?
|
| Violence | 2 | 2017 | 149 | 0.160 |
Why?
|
| Health Policy | 1 | 2020 | 185 | 0.160 |
Why?
|
| Rumination, Cognitive | 1 | 2017 | 1 | 0.150 |
Why?
|
| Behavioral Sciences | 1 | 2017 | 2 | 0.150 |
Why?
|
| Avoidance Learning | 1 | 2017 | 22 | 0.150 |
Why?
|
| Psychological Trauma | 1 | 2017 | 21 | 0.150 |
Why?
|
| Alcoholism | 1 | 2021 | 306 | 0.150 |
Why?
|
| Rape | 1 | 2016 | 14 | 0.140 |
Why?
|
| Social Perception | 1 | 2016 | 36 | 0.140 |
Why?
|
| Psychiatric Status Rating Scales | 3 | 2013 | 384 | 0.130 |
Why?
|
| Adult | 8 | 2021 | 15734 | 0.120 |
Why?
|
| Sexual and Gender Minorities | 1 | 2016 | 73 | 0.120 |
Why?
|
| Fluoxetine | 2 | 2011 | 44 | 0.110 |
Why?
|
| Suicidal Ideation | 1 | 2013 | 113 | 0.100 |
Why?
|
| Hypericum | 1 | 2011 | 5 | 0.100 |
Why?
|
| Plant Preparations | 1 | 2011 | 16 | 0.090 |
Why?
|
| Phytotherapy | 1 | 2011 | 52 | 0.090 |
Why?
|
| Middle Aged | 5 | 2020 | 16236 | 0.090 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2011 | 137 | 0.090 |
Why?
|
| Clonazepam | 1 | 2010 | 3 | 0.090 |
Why?
|
| Male | 11 | 2024 | 27483 | 0.090 |
Why?
|
| Nervous System Diseases | 1 | 2011 | 95 | 0.080 |
Why?
|
| Narcotic Antagonists | 2 | 2021 | 114 | 0.080 |
Why?
|
| Double-Blind Method | 4 | 2012 | 684 | 0.080 |
Why?
|
| Evoked Potentials, Auditory | 1 | 2008 | 10 | 0.080 |
Why?
|
| Female | 11 | 2024 | 30806 | 0.080 |
Why?
|
| Sound | 1 | 2008 | 11 | 0.080 |
Why?
|
| Stress, Psychological | 1 | 2013 | 443 | 0.080 |
Why?
|
| Alcohol Drinking | 2 | 2021 | 299 | 0.080 |
Why?
|
| Speech Perception | 1 | 2008 | 79 | 0.070 |
Why?
|
| Prevalence | 2 | 2024 | 1279 | 0.070 |
Why?
|
| Aging | 1 | 2011 | 723 | 0.060 |
Why?
|
| Depression | 1 | 2013 | 857 | 0.060 |
Why?
|
| Comorbidity | 2 | 2024 | 1086 | 0.060 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2011 | 675 | 0.060 |
Why?
|
| Cardiovascular Diseases | 1 | 2011 | 827 | 0.050 |
Why?
|
| Time Factors | 4 | 2012 | 3567 | 0.050 |
Why?
|
| Sex Characteristics | 1 | 2024 | 199 | 0.050 |
Why?
|
| Young Adult | 4 | 2016 | 4319 | 0.050 |
Why?
|
| Demography | 2 | 2013 | 178 | 0.050 |
Why?
|
| Sex Factors | 1 | 2024 | 959 | 0.050 |
Why?
|
| Buprenorphine, Naloxone Drug Combination | 1 | 2021 | 26 | 0.050 |
Why?
|
| Injections, Intramuscular | 1 | 2021 | 69 | 0.050 |
Why?
|
| Delayed-Action Preparations | 1 | 2021 | 105 | 0.050 |
Why?
|
| Narcotics | 1 | 2020 | 50 | 0.040 |
Why?
|
| Naltrexone | 1 | 2021 | 76 | 0.040 |
Why?
|
| Regression Analysis | 2 | 2011 | 485 | 0.040 |
Why?
|
| Arousal | 1 | 2020 | 42 | 0.040 |
Why?
|
| Recurrence | 1 | 2022 | 576 | 0.040 |
Why?
|
| Afghan Campaign 2001- | 1 | 2020 | 54 | 0.040 |
Why?
|
| Iraq War, 2003-2011 | 1 | 2020 | 57 | 0.040 |
Why?
|
| Methadone | 1 | 2020 | 126 | 0.040 |
Why?
|
| Pilot Projects | 2 | 2012 | 919 | 0.040 |
Why?
|
| Ethanol | 1 | 2021 | 307 | 0.040 |
Why?
|
| Internet | 1 | 2020 | 458 | 0.030 |
Why?
|
| Accidents, Traffic | 1 | 2017 | 150 | 0.030 |
Why?
|
| Culture | 1 | 2016 | 76 | 0.030 |
Why?
|
| Pandemics | 1 | 2020 | 606 | 0.030 |
Why?
|
| Focus Groups | 1 | 2016 | 290 | 0.030 |
Why?
|
| Adolescent | 2 | 2016 | 5916 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2021 | 3095 | 0.030 |
Why?
|
| Quality of Life | 1 | 2020 | 1109 | 0.030 |
Why?
|
| Psychology, Comparative | 1 | 2013 | 1 | 0.030 |
Why?
|
| Self-Assessment | 1 | 2013 | 54 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2017 | 1448 | 0.030 |
Why?
|
| Executive Function | 1 | 2013 | 62 | 0.030 |
Why?
|
| Acupuncture Points | 1 | 2012 | 3 | 0.030 |
Why?
|
| Educational Measurement | 1 | 2013 | 207 | 0.020 |
Why?
|
| Sertraline | 1 | 2011 | 59 | 0.020 |
Why?
|
| Placebos | 1 | 2011 | 72 | 0.020 |
Why?
|
| Remission Induction | 1 | 2011 | 137 | 0.020 |
Why?
|
| Outpatients | 1 | 2011 | 131 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2013 | 781 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2010 | 187 | 0.020 |
Why?
|
| Motor Activity | 1 | 2013 | 342 | 0.020 |
Why?
|
| Anti-Anxiety Agents | 1 | 2010 | 31 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2021 | 5975 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2010 | 354 | 0.020 |
Why?
|
| Verbal Learning | 1 | 2008 | 19 | 0.020 |
Why?
|
| Acoustic Stimulation | 1 | 2008 | 50 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2010 | 434 | 0.020 |
Why?
|
| Electroencephalography | 1 | 2008 | 136 | 0.020 |
Why?
|
| Logistic Models | 1 | 2011 | 1252 | 0.020 |
Why?
|
| Research Design | 1 | 2011 | 565 | 0.020 |
Why?
|
| United States | 1 | 2020 | 7493 | 0.020 |
Why?
|
| Age Factors | 1 | 2011 | 1518 | 0.020 |
Why?
|
| Brain Mapping | 1 | 2008 | 230 | 0.020 |
Why?
|
| Aged | 2 | 2012 | 13290 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2013 | 1907 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2013 | 2462 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2011 | 2323 | 0.020 |
Why?
|
| Risk Factors | 1 | 2013 | 4999 | 0.010 |
Why?
|